Oxurion NV is a company specializing in acquiring majority stakes in promising European pharmaceutical subcontractors. Oxurion NV's ambition is to build an integrated group of subcontractors serving healthcare players. Oxurion NV holds a 72% stake in Axiodis CRO, a subcontractor specialized in biometrics.

Employees

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-07-13	€0.002800	-6.67%	160,758
26-07-10	€0.003000	+15.38%	1,689,333
26-07-09	€0.002600	-7.14%	418,256
26-07-08	€0.002800	0.00%	2,770,002
26-07-07	€0.002800	0.00%	2,971,658

Real-time Euronext Bruxelles

More quotes

Income Statement and Estimates

More financial data

Market Closed - Euronext Bruxelles Other stock markets 11:55:00 2026-07-13 EDT			5-day change	1st Jan Change
0.002800 ^EUR	-6.67%		-6.67%	-61.11%

06-02	Oxurion Positions Itself in the GLP-1 Therapy Market
06-02	Oxurion Ends Talks to Buy Majority Stake in France-based CRO	MT

Market Cap	248K 283K 230K 212K 400K 27.1M 408K 2.74M 1.08M 13.31M 1.06M 1.04M 45.96M	P/E 2024	2.56x	P/E 2025	-0.05x
Enterprise Value	11.26M 12.84M 10.43M 9.6M 18.15M 1.23B 18.5M 124M 48.75M 603M 48.21M 47.15M 2.08B	EV / Sales 2024	3,879x	EV / Sales 2025	20.7x
Free-Float	78.02%	Yield 2024 *	-	Yield 2025	-

06-02	Oxurion Positions Itself in the GLP-1 Therapy Market
06-02	Oxurion Ends Talks to Buy Majority Stake in France-based CRO	MT
04-29	Oxurion NV Auditor Raises 'Going Concern' Doubt	CI
04-29	Oxurion NV Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-19	Oxurion NV signs a letter of intent for acquisition of an International CRO	RE
03-01	Oxurion Extends Talks for Acquisition of Majority Stake in French CRO	MT
01-19	Oxurion Temporarily Suspends Digital Assets Investment Project Amid Crypto Volatility	MT
25-10-14	Oxurion to Acquire Majority Stake in French Contract Research Organization	MT
25-10-01	Oxurion NV Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-08-05	Oxurion Receives Improved EUR30 Million Indicative Financing Offer from Atlas Special	MT
25-07-22	Oxurion Plans EUR10 Million Bond Issue to Fund Treasury Diversification	MT
25-07-21	Oxurion NV announced that it expects to receive ?10 million in funding from Atlas Special Opportunities LLC	CI
25-07-17	Oxurion Secures Financing for Axiodis Stake Acquisition	MT

07-06	Oxurion Nv : Oxurion achieves another milestone in the expansion of the Exagis platform with the commercial launch of its eTMF module	AT
06-26	Oxurion Nv : Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC	AT
06-24	Oxurion Nv : Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC	AT
06-19	Oxurion Nv : Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC	AT
06-15	Oxurion Nv : Major market validation: Pierre Fabre Laboratories uses Oxurion’s Exagis Platform	AT

Oxurion NV Stock

Stocks

OXUR

BE0974487192

Biotechnology & Medical Research

Valuation: Oxurion NV

Chart: Oxurion NV

Latest news : Oxurion NV

Press Releases: Oxurion NV

News in other languages: Oxurion NV

Quotes and Performance

Course Extremes

Managers and Directors: Oxurion NV

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

07-08	Oxurion Nv : Informatie met betrekking tot het Totaal Aantal Stemrechten (Noemer) volgend op Atlas Conversie-Notificatie
07-06	Oxurion Nv : Oxurion bereikt een nieuwe mijlpaal in de uitbouw van het Exagis-platform met de commerciële lancering van zijn eTMF-module
07-06	Oxurion Nv : Oxurion franchit une nouvelle étape dans le développement de sa plateforme Exagis avec le lancement commercial de son module eTMF
06-26	Oxurion Nv : Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC
06-24	Oxurion Nv : Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC

1 day	-6.67%
1 week	-6.67%
1 month	-6.67%
3 months	-36.36%
6 months	-63.16%
Current year	-61.11%

Manager	Title	Age	Since
Ghoson Pascal CEO	Chief Executive Officer	37	2023-12-27
Philippe Barbeaux CTO	Chief Tech/Sci/R&D Officer	-	2023-12-27
Samuel Darcheville SEC	Corporate Secretary	-	2023-12-27

Director	Title	Age	Since
Ghoson Pascal BRD	Director/Board Member	37	2023-12-27
James Hartmann BRD	Director/Board Member	60	2023-12-27
Charles Paris de Bollardire CHM	Chairman	-	2023-12-27

Date	Insider	Type	Main position	Quantity	% Market Cap.
22-03-10	Midelco NV	Buy	Company	1,180	0.0030%
22-03-10	Ecp Liquid Fund 1 LLC	Buy	Company	1,180	0.0030%
21-11-16	Thomas Clay	Buy	Chairman	2,766	0.0072%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
OXURION NV	-6.67%	-6.67%	-89.71%	-99.98%	304K
LONZA GROUP AG	+0.44%	+2.51%	+4.36%	+10.27%	50.73B
REVOLUTION MEDICINES, INC.	-1.57%	-3.18%	+379.41%	+593.37%	39.73B
IQVIA HOLDINGS INC.	-0.14%	+0.77%	+29.61%	-5.50%	34.69B
BEONE MEDICINES AG	+1.76%	-1.78%	+20.55%	+53.38%	33.21B
CELLTRION, INC.	-0.06%	-4.63%	+2.94%	+31.65%	26.76B
ASCENDIS PHARMA A/S	-1.93%	-1.01%	-	-	16.8B
MEDPACE HOLDINGS, INC.	-1.49%	-6.18%	+65.50%	+120.53%	15.37B
EUROFINS SCIENTIFIC SE	+0.78%	+0.20%	+14.69%	+17.08%	13.78B
ICON PUBLIC LIMITED COMPANY	-0.97%	-2.83%	+11.09%	-33.29%	12.85B
Average	-1.01%	-0.88%	+48.72%	+76.39%	24.39B
Weighted average by Cap.	-0.24%	-0.38%	+81.17%	+124.10%

	2024	2025
Net sales	3K 3.42K 2.78K 2.56K 4.84K 327K 4.93K 33.12K 12.99K 161K 12.84K 12.56K 555K	555K 633K 514K 473K 895K 60.56M 912K 6.13M 2.4M 29.74M 2.38M 2.32M 103M
Net income	119K 136K 110K 101K 192K 12.99M 196K 1.31M 515K 6.38M 509K 498K 22.02M	-3.73M -4.25M -3.45M -3.18M -6.01M -407M -6.13M -41.15M -16.14M -200M -15.96M -15.61M -690M
Net Debt	10.87M 12.4M 10.07M 9.27M 17.52M 1.19B 17.87M 120M 47.07M 583M 46.55M 45.53M 2.01B	11.01M 12.56M 10.2M 9.38M 17.75M 1.2B 18.1M 122M 47.68M 590M 47.15M 46.11M 2.04B

1 week	0		0
1 month	0		0
Current year	0		0.01
1 year	0		0.08
3 years	0		49
5 years	0		25,900
10 years	0		104,600